ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1916

Reduced DNASE1L3 Activity in Sporadic SLE Is Linked to Increased DNA Load of Microparticles, Reactivity to DNASE1L3-sensitive Antigens, and Lupus Nephritis

Johannes Hartl1, Robert Clancy 1, Peter Izmirly 1, H Michael Belmont 2, Catherine Trad 1, Nicole Bornkamp 1, Vanja Sisirak 1, Benjamin Sally 1, Jill Buyon 1 and Boris Reizis 1, 1NYU School of Medicine, New York, 2NYU Langone Health, New York, NY

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: anti-DNA and lupus nephritis, Microparticles

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, November 11, 2019

Title: 4M120: SLE – Clinical IV: Lupus Nephritis (1914–1919)

Session Type: ACR Abstract Session

Session Time: 4:30PM-6:00PM

Background/Purpose: Null mutations in DNASE1L3 cause severe familial SLE with prominent anti-DNA antibodies (Abs), suggesting that DNASE1L3 is a key driver of tolerance to DNA. Indeed, DNASE1L3-deficient mice rapidly develop anti-chromatin and anti-DNA Abs followed by renal involvement. DNASE1L3 is a secreted DNase that has the preferential capacity to digest DNA within nucleosomes and/or encapsulated by membranes. Our previous studies suggest that chromatin carried by circulating apoptotic microparticles (MP) is an important physiological substrate of DNASE1L3. Accordingly, the present study was initiated to address the hypothesis that dysfunction of DNASE1L3 and its downstream consequences contribute to the development of sporadic human SLE.

Methods: Reactivity to DNASE1L3-sensitive antigens on MP was measured by incubating plasma samples with control or DNASE1L3-treated MP and analyzing IgG binding to MP by flow cytometry.  DNASE1L3 activity was measured based on its preferential capacity to digest complex DNA substrates with the readout expressed as the fraction of activity measured in healthy control subjects. The DNA load of MP was measured by qPCR of genomic DNA purified from the MP and MP-depleted fractions of plasma. In considering a spectrum from benign to clinical autoimmunity, subjects included those with active biopsy proven lupus nephritis as well as those with anti-Ro antibodies absent SLE.

Results: IgG-binding to MP was assessed in 116 SLE patients, 45 anti-Ro Ab-positive mothers whose children have neonatal lupus (17 asymptomatic or having an undifferentiated autoimmune syndrome, 2 SLE, 12 SS, 14 SLE/SS) and 16 healthy controls. IgG-reactivity to MP was not detected in any healthy controls. In contrast, 36% of SLE patients showed IgG binding to MP reversed by DNASE1L3 pretreatment (DNASE1L3-senstive reactivity). Only two of these patients were heterozygous for the known hypomorphic DNASE1L3 (R206C) variant. DNASE1L3-sensitive reactivity correlated with anti-dsDNA Abs (p< .0001) but did not overlap, indicating that reactivity is directed to more complex DNA. DNASE1L3-sensitive reactivity correlated with active proteinuria (p=.0003), low complement levels (p=.01) and overall SLEDAI (p< .0001). Among 45 anti-Ro-positive mothers, all were unreactive except the only 2 SLE mothers that developed lupus nephritis. The DNA load of MP and DNASE1L3 activity were assessed in a subset of SLE patients (n=40). Of these, patients with proteinuria showed lower plasma DNASE1L3 activity (p=.034) than those without proteinuria (Fig. 1). Moreover, increased partitioning of plasma DNA into MP correlated with reduced DNASE1L3 activity, and both parameters strongly correlated with DNASE1L3-sensitive IgG binding to MPs (p< 0.0001) (Fig. 2).

Conclusion: The activity of plasma DNASE1L3 is reduced in a significant fraction of SLE patients with renal disorder unrelated to a genetic explanation and is associated with DNA accumulation in MP targeted by Abs. Collectively, these data suggest that digestion of circulating chromatin by DNASE1L3 is a fundamental mechanism of tolerance to DNA which when disrupted may lead to sporadic SLE, particularly lupus nephritis.


Figure 1

Figure 1. DNASE1L3 activity in SLE patients with and without proteinuria measured as a percentage of baseline activity in healthy controls.


Figure 2

Figure 2. Cell-free DNA bound to microparticles -cfDNA MP fraction- as a percentage of total DNA in DNASE1L3-sensitive versus insensitive patient samples -left panel-; DNASE1L3 activity in in DNASE1L3-sensitive versus insensitive patient samples measured as a percentage of baseline activity in healthy controls -right panel-.


Disclosure: J. Hartl, None; R. Clancy, Bristol Myers Squibb, 5, Exagen Diagnostics, 2; P. Izmirly, GlaxoSmithKline, 5; H. Belmont, None; C. Trad, None; N. Bornkamp, None; V. Sisirak, None; B. Sally, None; J. Buyon, Bristol Myers Squibb, 5, Exagen Diagnostics, 2; B. Reizis, None.

To cite this abstract in AMA style:

Hartl J, Clancy R, Izmirly P, Belmont H, Trad C, Bornkamp N, Sisirak V, Sally B, Buyon J, Reizis B. Reduced DNASE1L3 Activity in Sporadic SLE Is Linked to Increased DNA Load of Microparticles, Reactivity to DNASE1L3-sensitive Antigens, and Lupus Nephritis [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/reduced-dnase1l3-activity-in-sporadic-sle-is-linked-to-increased-dna-load-of-microparticles-reactivity-to-dnase1l3-sensitive-antigens-and-lupus-nephritis/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/reduced-dnase1l3-activity-in-sporadic-sle-is-linked-to-increased-dna-load-of-microparticles-reactivity-to-dnase1l3-sensitive-antigens-and-lupus-nephritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology